Omalizumab as a premedication in venom immunotherapy: When is it indicated in systemic mastocytosis?

dc.contributor.author	Buyukozturk, S.
dc.contributor.author	Yegit, O. O.
dc.contributor.author	Unal, D.
dc.contributor.author	Colakoglu, B.
dc.contributor.author	Demir, S.
dc.contributor.author	Gelincik, A.
dc.date.accessioned	2021-03-03T07:32:21Z
dc.date.available	2021-03-03T07:32:21Z
dc.identifier.citation	Yegit O. O. , Demir S., Unal D., Colakoglu B., Buyukozturk S., Gelincik A., "Omalizumab as a premedication in venom immunotherapy: When is it indicated in systemic mastocytosis?", Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Lisbon, Portekiz, 1 - 05 Haziran 2019, cilt.74, ss.525-526
dc.identifier.other	vv_1032021
dc.identifier.other	av_128e90f6-41d4-4134-9b13-27f6257e298e
dc.identifier.uri	http://hdl.handle.net/20.500.12627/17919
dc.language.iso	eng
dc.subject	İmmünoloji
dc.subject	Yaşam Bilimleri (LIFE)
dc.subject	Tıp
dc.subject	Sağlık Bilimleri
dc.subject	Yaşam Bilimleri
dc.subject	Temel Bilimler
dc.subject	ALERJİ
dc.subject	Klinik Tıp
dc.subject	Klinik Tıp (MED)
dc.title	Omalizumab as a premedication in venom immunotherapy: When is it indicated in systemic mastocytosis?
dc.type	Bildiri
dc.contributor.department	İstanbul Üniversitesi , ,
dc.identifier.volume	74
dc.contributor.firstauthorID	156663

Files in this item

Files	Size	Format	View
There are no files associated with this item.